OTC nasal spray seemed to cut Covid infections by 67% in mid-sized trial
8 days ago
- #antihistamine
- #clinical-trial
- #COVID-19
- Azelastine nasal spray may reduce COVID-19 infections by 67% in a mid-stage trial.
- The Phase 2 trial involved 450 healthy adults, with half using the antihistamine spray and half a placebo.
- Only 2.2% of spray users got COVID-19 vs. 6.7% in the placebo group, showing a significant reduction.
- Spray users who contracted COVID-19 took longer to get infected and cleared the virus faster.
- The spray also reduced overall respiratory infections, particularly rhinovirus (common cold).
- Azelastine may have a general antiviral mechanism, but the exact process is unclear.